Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
grade D 0.9 7.72% 0.06
IBIO closed up 7.72 percent on Monday, March 18, 2019, on 1.77 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IBIO trend table...

Date Alert Name Type % Chg
Mar 18 Crossed Above 200 DMA Bullish 0.00%
Mar 18 Crossed Above 20 DMA Bullish 0.00%
Mar 18 Crossed Above 50 DMA Bullish 0.00%
Mar 18 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 200 DMA Resistance Bearish 7.72%
Mar 15 20 DMA Resistance Bearish 7.72%
Mar 15 50 DMA Resistance Bearish 7.72%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.72%
Mar 15 Wide Bands Range Expansion 7.72%

Older signals for IBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Medicine Biotechnology Alpha Disorders Influenza Vaccination Microbiology Vaccines Biopharmaceuticals Hereditary Angioedema Fabry Disease Seasonal Influenza Deficiency H5n1 Clinical Trials Treatment Of Fabry Disease Human Papilloma Virus Influenza Vaccines
Is IBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.6
52 Week Low 0.495
Average Volume 89,278
200-Day Moving Average 0.8521
50-Day Moving Average 0.8661
20-Day Moving Average 0.8663
10-Day Moving Average 0.8105
Average True Range 0.0825
ADX 15.02
+DI 18.181
-DI 14.3922
Chandelier Exit (Long, 3 ATRs ) 0.8525
Chandelier Exit (Short, 3 ATRs ) 0.9675
Upper Bollinger Band 1.0102
Lower Bollinger Band 0.7224
Percent B (%b) 0.62
BandWidth 33.221748
MACD Line -0.0111
MACD Signal Line -0.0121
MACD Histogram 0.0009
Fundamentals Value
Market Cap 83.53 Million
Num Shares 92.8 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -5.49
Price-to-Sales 74.56
Price-to-Book 3.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.02
Resistance 3 (R3) 1.01 0.96 1.00
Resistance 2 (R2) 0.96 0.93 0.96 0.99
Resistance 1 (R1) 0.93 0.91 0.94 0.94 0.99
Pivot Point 0.88 0.88 0.89 0.89 0.88
Support 1 (S1) 0.85 0.85 0.87 0.86 0.81
Support 2 (S2) 0.80 0.83 0.81 0.81
Support 3 (S3) 0.77 0.80 0.80
Support 4 (S4) 0.78